Documents

Q1 FY27 delivered 25% revenue and 36% EBITDA growth, with strong outlook and robust CDMO pipeline.

Record Q4 revenue and EBITDA, strong specialty and nutrition growth, and positive FY 2027 outlook.

Volume growth and margin resilience offset pricing headwinds; CDMO and FTAs drive future upside.

Record quarterly revenue and volume growth driven by specialty chemicals and CDMO momentum.

EBITDA rose 29% and PAT 54% year-on-year, led by Specialty and Nutrition growth.

Q4 PAT surged 153% YoY, led by specialty and nutrition growth, with robust margin expansion.

Specialty chemicals and nutrition drove robust Q3 growth, with EBITDA up 42% year-on-year.

Strong Q2 growth, major CDMO wins, and digital leadership drive positive outlook.

Specialty chemicals and cost savings drove strong EBITDA growth, with margins set to improve further.